S-33 SMR Shoulder HP Reverse Glenosphere
NCT: NCT05339815 · COMPLETED
Brief Summary
Study Design: Single arm, retrospective and prospective, single center, post-market clinical study Purpose:To demonstrate the safety and effectiveness of the SMR Reverse HP Shoulder System device for primary, fracture or revision total shoulder replacement out to 24 months. The eligible study population is the entire population that underwent a reverse shoulder arthroplasty performed with 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres between January 1, 2013 and January 1, 2020 at Wrightington Hospital (UK) in accordance with the indication for use of the product.
Frequently Asked Questions
What is S-33 SMR Shoulder HP Reverse Glenosphere?
S-33 SMR Shoulder HP Reverse Glenosphere is a clinical trial registered under NCT05339815. Current status: COMPLETED.
What is the status of NCT05339815?
The current status of NCT05339815 (S-33 SMR Shoulder HP Reverse Glenosphere) is: COMPLETED.
When did S-33 SMR Shoulder HP Reverse Glenosphere start?
S-33 SMR Shoulder HP Reverse Glenosphere started on 2022-10-17.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.